I think it's really to do with program design and targeting specific areas. Also, I know the government is very interested in putting more money into venture capital. That's very important. But Canada is a little too much of a risk-averse country. It's a cultural thing. I think we need to take more risk up front with that money. So whether that goes into BDC or other vehicles of venture funding, it needs to be more risky than it has been.
Second, for the genomic applications partnership program, we're going to be working very closely with IRAP, which has a fantastic lens to the industry side that we're certainly not going to recreate. Working with them will build a lot of value. It's not so much to do with structural changes; it's people on the ground, devising new programs and getting people excited about working together across the academia-industry divide. This will make a big difference.